Cash, cash equivalents and investments were $172.9M as of September 30, compared with $245.2M as of December 31, 2022. Net cash used in operations was $74.5M for the nine months ended September 30, compared with $56.8M for the nine months ended September 30, 2022.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ATHA:
- Athira Pharma to Participate in Jefferies London Healthcare Conference
- Athira Pharma presents data on potential benefit of ATH-1105 for ALS at NEALS
- Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
- Athira Pharma management to meet with JMP Securities
- Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference